TapewireFind a company

organization · Reporting owner

Atlas Venture Associates Opportunity I, LLC

Disclosed activity across 14 companies

Tapewire entity
67262
SEC CIK
0001780066

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Akero Therapeutics, Inc.AKRO · Entity 7198410% ownerJune 24, 2019June 25, 2019
Day One Biopharmaceuticals, Inc.DAWN · Entity 5118010% ownerJune 17, 2022June 22, 2022
Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813See remarksJune 29, 2020July 13, 2020
Dyne Therapeutics, Inc.DYN · Entity 394810% ownerMarch 01, 2024March 05, 2024
ImageneBio, Inc.IKNA · Entity 713910% ownerMarch 30, 2021December 15, 2021
Kymera Therapeutics, Inc.KYMR · Entity 354510% ownerMarch 11, 2024March 13, 2024
Q32 Bio Inc.QTTB · Entity 559410% ownerMarch 25, 2024March 27, 2024
Replimune Group, Inc.REPL · Entity 4707See RemarksNovember 18, 2019November 20, 2019
Tectonic Therapeutic, Inc.AVRO · Entity 5328See RemarksJuly 19, 2019July 30, 2019
Third Harmonic Bio, Inc.THRD · Entity 7651710% ownerSeptember 19, 2022September 19, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote3,469,759 Reported balance After 2019-06-24 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2019-06-24 · Conversion · Acquired 3,469,759 · Balance 3,469,759

F1: Represents the total number of shares of common stock received by Atlas Venture Fund XI, L.P. ("AVF XI") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.

F4: These shares are owned directly by AVF XI. Atlas Venture Associates XI, L.P., ("AVA XI LP") is the general partner of AVF XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVF XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee Footnote235,099 Reported balance After 2019-06-24 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2019-06-24 · Conversion · Acquired 235,099 · Balance 235,099

F3: Represents the total number of shares of common stock received by Atlas Opportunity Fund I, L.P. ("AVO I") upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.

F5: These shares are owned directly by AVO I. Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVO I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVO I, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee Footnote505,099 Reported balance After 2019-06-24 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2019-06-24 · Purchase · Acquired 270,000 · Balance 505,099

F6: On June 24, 2019, AVO I purchased 270,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering.

F5: These shares are owned directly by AVO I. Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVO I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVO I, except to the extent of its pecuniary interest therein, if any.

Series A Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2019-06-24 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2019-06-24 · Conversion · Disposed 10,666,667 · Balance 0

F2: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.

F4: These shares are owned directly by AVF XI. Atlas Venture Associates XI, L.P., ("AVA XI LP") is the general partner of AVF XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVF XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2019-06-24 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2019-06-24 · Conversion · Disposed 722,737 · Balance 0

F2: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.

F5: These shares are owned directly by AVO I. Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVO I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVO I, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the total number of shares of common stock received by Atlas Venture Fund XI, L.P. ("AVF XI") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.

F3: Represents the total number of shares of common stock received by Atlas Opportunity Fund I, L.P. ("AVO I") upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

F4: These shares are owned directly by AVF XI. Atlas Venture Associates XI, L.P., ("AVA XI LP") is the general partner of AVF XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVF XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.

F5: These shares are owned directly by AVO I. Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVO I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVO I, except to the extent of its pecuniary interest therein, if any.

F6: On June 24, 2019, AVO I purchased 270,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect766,667 Reported balance After 2022-06-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2022-06-17 · Purchase · Acquired 766,667 · Balance 766,667

F1: The shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote7,210,242 Reported balance Holding disclosure · report date 2022-06-17 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 7,210,242

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote15,714 Reported balance Holding disclosure · report date 2022-06-17 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 15,714

F3: The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote991,396 Reported balance Holding disclosure · report date 2022-06-17 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 991,396

F4: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

F3: The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of its pecuniary interest therein, if any.

F4: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Dianthus Therapeutics, Inc. /DE/

Report date June 29, 2020 · Filed July 13, 2020

Jointly reported with Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,250,000 Reported balance Holding disclosure · report date 2020-06-29 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 1,250,000

F1: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,458,691 Reported balance After 2024-03-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-03-01 · Sale · Disposed 29,435 · Balance 1,458,691

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote847,388 Reported balance After 2024-03-01 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2024-03-01 · Sale · Disposed 17,099 · Balance 847,388

F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F5: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote874,634 Reported balance After 2021-03-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2021-03-30 · Purchase · Acquired 125,000 · Balance 874,634

F1: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeDirect1,241,935 Last balance in matching sequence After 2021-12-14 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 2 · 2021-12-10 · Sale · Disposed 11,989 · Balance 1,256,224

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.55 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4).

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Row 3 · 2021-12-13 · Sale · Disposed 8,330 · Balance 1,247,894

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.65 inclusive.

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Row 4 · 2021-12-14 · Sale · Disposed 5,959 · Balance 1,241,935

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.55 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4).

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.65 inclusive.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect4,676,075 Last balance in matching sequence After 2024-03-13 transaction · row 10 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rows

Row 1 · 2024-03-11 · Sale · Disposed 37,180 · Balance 4,930,934

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.1826 to $43.18 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7), (8), (9) and (10).

F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

Row 2 · 2024-03-11 · Sale · Disposed 5,122 · Balance 4,925,812

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.185 to $44.03 inclusive.

F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

Row 5 · 2024-03-12 · Sale · Disposed 126,066 · Balance 4,799,746

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.445 to $42.43 inclusive.

F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

Row 6 · 2024-03-12 · Sale · Disposed 8,581 · Balance 4,791,165

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.46 to $42.90 inclusive.

F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

Row 9 · 2024-03-13 · Sale · Disposed 108,404 · Balance 4,682,761

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $42.475 inclusive.

F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

Row 10 · 2024-03-13 · Sale · Disposed 6,686 · Balance 4,676,075

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6032 to $43.0839 inclusive.

F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote828,830 Last balance in matching sequence After 2024-03-13 transaction · row 12 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rows

Row 3 · 2024-03-11 · Sale · Disposed 7,837 · Balance 882,311

F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.1826 to $43.18 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7), (8), (9) and (10).

F6: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Row 4 · 2024-03-11 · Sale · Disposed 1,045 · Balance 881,266

F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.185 to $44.03 inclusive.

F6: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Row 7 · 2024-03-12 · Sale · Disposed 26,452 · Balance 854,814

F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.445 to $42.43 inclusive.

F6: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Row 8 · 2024-03-12 · Sale · Disposed 1,819 · Balance 852,995

F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.46 to $42.90 inclusive.

F6: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Row 11 · 2024-03-13 · Sale · Disposed 22,779 · Balance 830,216

F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $42.475 inclusive.

F6: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Row 12 · 2024-03-13 · Sale · Disposed 1,386 · Balance 828,830

F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6032 to $43.0839 inclusive.

F6: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.1826 to $43.18 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7), (8), (9) and (10).

F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.185 to $44.03 inclusive.

F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.

F6: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.445 to $42.43 inclusive.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.46 to $42.90 inclusive.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $42.475 inclusive.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6032 to $43.0839 inclusive.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect864,261 Reported balance Holding disclosure · report date 2024-03-25 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 864,261

F1: Shares held by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectBy Atlas Venture Opportunity Fund I, L.P.503,296 Reported balance Holding disclosure · report date 2024-03-25 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 503,296

F2: Shares held by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectBy Atlas Venture Opportunity Fund II, L.P.724,549 Reported balance Holding disclosure · report date 2024-03-25 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 724,549

F3: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Shares held by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

F2: Shares held by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

F3: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.

Replimune Group, Inc.

Report date November 18, 2019 · Filed November 20, 2019

Jointly reported with Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote1,100,000 Reported balance Holding disclosure · report date 2019-11-18 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 1,100,000

F1: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Tectonic Therapeutic, Inc.

Report date July 19, 2019 · Filed July 30, 2019

Jointly reported with Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote810,811 Reported balance Holding disclosure · report date 2019-07-19 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 810,811

F1: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect10,013,763 Reported balance After 2022-09-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2022-09-19 · Conversion · Acquired 6,472,374 · Balance 10,013,763

F1: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeDirect10,313,763 Reported balance After 2022-09-19 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2022-09-19 · Purchase · Acquired 300,000 · Balance 10,313,763

F3: On September 19, 2022, Atlas Venture Fund XI purchased 300,000 shares of common stock of the Issuer at a purchase price of $17.00 per share pursuant to an underwritten public offering.

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeDirect594,096 Reported balance After 2022-09-19 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2022-09-19 · Conversion · Acquired 594,096 · Balance 594,096

F1: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F4: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Series A-1 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-09-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2022-09-19 · Conversion · Disposed 3,541,390 · Balance 0

F1: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Series A-2 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-09-19 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2022-09-19 · Conversion · Disposed 2,282,537 · Balance 0

F1: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Series A-3 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-09-19 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2022-09-19 · Conversion · Disposed 648,447 · Balance 0

F1: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Series B Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-09-19 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2022-09-19 · Conversion · Disposed 594,096 · Balance 0

F1: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F5: The balance has been reduced by one share to adjust for an overstatemnet of one share in Reporting Person's Form 3 filed on September 14, 2022.

F4: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

F3: On September 19, 2022, Atlas Venture Fund XI purchased 300,000 shares of common stock of the Issuer at a purchase price of $17.00 per share pursuant to an underwritten public offering.

F4: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

F5: The balance has been reduced by one share to adjust for an overstatemnet of one share in Reporting Person's Form 3 filed on September 14, 2022.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Section 16 reporting ended · disclosed 2024-01-25. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,402,186 Reported balance After 2024-01-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-01-23 · Sale · Disposed 47,500 · Balance 1,402,186

F1: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote703,660 Reported balance After 2024-01-23 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2024-01-23 · Sale · Disposed 82,500 · Balance 703,660

F2: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote198,326 Reported balance After 2024-01-23 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2024-01-23 · Sale · Disposed 20,000 · Balance 198,326

F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("Atlas Opportunity II"). Atlas Venture Associates Opportunity II, L.P. ("Associates II") is the general partner of Atlas Opportunity II. Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. Each of Associates II and Associates II LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity II, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

F2: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.

F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("Atlas Opportunity II"). Atlas Venture Associates Opportunity II, L.P. ("Associates II") is the general partner of Atlas Opportunity II. Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. Each of Associates II and Associates II LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity II, except to the extent of its pecuniary interest therein, if any.

Section 16 reporting ended · disclosed 2026-02-09. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2026-02-09 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2026-02-09 · Other · Disposed 711,193 · Balance 0

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F3: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2026-02-09 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2026-02-09 · Other · Disposed 116,693 · Balance 0

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F4: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, LP ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2026-02-09 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2026-02-09 · Other · Disposed 60 · Balance 0

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F5: The shares are held directly by AVAO I LP. AVAO I LLC is the general partner of AVAO I LP. AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVAO I LP except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F3: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

F4: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, LP ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

F5: The shares are held directly by AVAO I LP. AVAO I LLC is the general partner of AVAO I LP. AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVAO I LP except to the extent of its pecuniary interest therein, if any.

Section 16 reporting ended · disclosed 2025-08-07. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2025-08-05 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2025-08-05 · Disposition to issuer · Disposed 4,808,896 · Balance 0

F1: The securities were disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. Each share of Issuer Common Stock issued and outstanding was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest plus (ii) one contingent value right, representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone.

F2: These shares were held directly by Atlas Venture Fund XII, L.P. ("Atlas Venture Fund XII"). The general partner of Atlas Venture Fund XII is Atlas Venture Associates XII, L.P. ("AVA XII LP"). Atlas Venture Associates XII, LLC ("AVA XII LLC") is the general partner of AVA XII LP. Each of AVA XII LP and AVA XII LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XII, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectBy Atlas Venture Opportunity Fund I, L.P.0 Reported balance After 2025-08-05 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2025-08-05 · Disposition to issuer · Disposed 1,027,978 · Balance 0

F1: The securities were disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. Each share of Issuer Common Stock issued and outstanding was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest plus (ii) one contingent value right, representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone.

F3: These shares were held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The securities were disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. Each share of Issuer Common Stock issued and outstanding was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest plus (ii) one contingent value right, representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone.

F2: These shares were held directly by Atlas Venture Fund XII, L.P. ("Atlas Venture Fund XII"). The general partner of Atlas Venture Fund XII is Atlas Venture Associates XII, L.P. ("AVA XII LP"). Atlas Venture Associates XII, LLC ("AVA XII LLC") is the general partner of AVA XII LP. Each of AVA XII LP and AVA XII LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XII, except to the extent of its pecuniary interest therein, if any.

F3: These shares were held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Section 16 reporting ended · disclosed 2024-02-09. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,019,563 Reported balance After 2024-02-08 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-02-08 · Sale · Disposed 733 · Balance 2,019,563

F1: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee footnote734,546 Reported balance After 2024-02-08 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2024-02-08 · Sale · Disposed 267 · Balance 734,546

F2: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

F2: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 09, 2026 Filed Feb 9, 2026 23:19 UTC Generation Bio Co. GBIO · Entity 67174 OtherCommon Stock 60 Not disclosed Not disclosed
Disclosure

SEC source: 0001231919-26-000124 · form4-02092026_110208.xml · nonDerivative · entry 3

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2 · kind: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2 · price: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F5 · ownership.nature: The shares are held directly by AVAO I LP. AVAO I LLC is the general partner of AVAO I LP. AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVAO I LP except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 09, 2026 Filed Feb 9, 2026 23:19 UTC Generation Bio Co. GBIO · Entity 67174 OtherCommon Stock 116,693 Not disclosed Not disclosed
Disclosure

SEC source: 0001231919-26-000124 · form4-02092026_110208.xml · nonDerivative · entry 2

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2 · kind: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2 · price: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F4 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, LP ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 09, 2026 Filed Feb 9, 2026 23:19 UTC Generation Bio Co. GBIO · Entity 67174 OtherCommon Stock 711,193 Not disclosed Not disclosed
Disclosure

SEC source: 0001231919-26-000124 · form4-02092026_110208.xml · nonDerivative · entry 1

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2 · kind: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2 · price: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

Read SEC document
August 05, 2025 Filed Aug 7, 2025 21:00 UTC Vigil Neuroscience, Inc. VIGL · Entity 11675 Disposition to issuerCommon Stock 1,027,978 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-021282 · form4-08072025_050805.xml · nonDerivative · entry 2

Atlas Venture Fund XII, L.P. · CIK 0001812049 · 10% owner

Atlas Venture Associates XII, L.P. · CIK 0001845875 · 10% owner

Atlas Venture Associates XII, LLC · CIK 0001845871 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Atlas Venture Opportunity Fund I, L.P.

Disclosed balance after: 0

F1 · kind: The securities were disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. Each share of Issuer Common Stock issued and outstanding was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest plus (ii) one contingent value right, representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone.

F1 · price: The securities were disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. Each share of Issuer Common Stock issued and outstanding was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest plus (ii) one contingent value right, representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone.

F3 · ownership.nature: These shares were held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
August 05, 2025 Filed Aug 7, 2025 21:00 UTC Vigil Neuroscience, Inc. VIGL · Entity 11675 Disposition to issuerCommon Stock 4,808,896 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-021282 · form4-08072025_050805.xml · nonDerivative · entry 1

Atlas Venture Fund XII, L.P. · CIK 0001812049 · 10% owner

Atlas Venture Associates XII, L.P. · CIK 0001845875 · 10% owner

Atlas Venture Associates XII, LLC · CIK 0001845871 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The securities were disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. Each share of Issuer Common Stock issued and outstanding was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest plus (ii) one contingent value right, representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone.

F1 · price: The securities were disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. Each share of Issuer Common Stock issued and outstanding was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest plus (ii) one contingent value right, representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone.

F2 · ownership.direct: These shares were held directly by Atlas Venture Fund XII, L.P. ("Atlas Venture Fund XII"). The general partner of Atlas Venture Fund XII is Atlas Venture Associates XII, L.P. ("AVA XII LP"). Atlas Venture Associates XII, LLC ("AVA XII LLC") is the general partner of AVA XII LP. Each of AVA XII LP and AVA XII LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XII, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 13, 2024 Filed Mar 13, 2024 23:53 UTC Kymera Therapeutics, Inc. KYMR · Entity 3545 SaleCommon Stock 1,386 $42.84 $59,376.24
Disclosure

SEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 12

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 828,830

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6032 to $43.0839 inclusive.

F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 13, 2024 Filed Mar 13, 2024 23:53 UTC Kymera Therapeutics, Inc. KYMR · Entity 3545 SaleCommon Stock 22,779 $42.19 $961,046.01
Disclosure

SEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 11

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 830,216

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $42.475 inclusive.

F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 13, 2024 Filed Mar 13, 2024 23:53 UTC Kymera Therapeutics, Inc. KYMR · Entity 3545 SaleCommon Stock 6,686 $42.84 $286,428.24
Disclosure

SEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 10

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,676,075

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6032 to $43.0839 inclusive.

F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 13, 2024 Filed Mar 13, 2024 23:53 UTC Kymera Therapeutics, Inc. KYMR · Entity 3545 SaleCommon Stock 108,404 $42.19 $4,573,564.76
Disclosure

SEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 9

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,682,761

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $42.475 inclusive.

F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 12, 2024 Filed Mar 13, 2024 23:53 UTC Kymera Therapeutics, Inc. KYMR · Entity 3545 SaleCommon Stock 1,819 $42.52 $77,343.88
Disclosure

SEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 8

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 852,995

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.46 to $42.90 inclusive.

F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 12, 2024 Filed Mar 13, 2024 23:53 UTC Kymera Therapeutics, Inc. KYMR · Entity 3545 SaleCommon Stock 26,452 $41.94 $1,109,396.88
Disclosure

SEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 7

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 854,814

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.445 to $42.43 inclusive.

F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 12, 2024 Filed Mar 13, 2024 23:53 UTC Kymera Therapeutics, Inc. KYMR · Entity 3545 SaleCommon Stock 8,581 $42.52 $364,864.12
Disclosure

SEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 6

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,791,165

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.46 to $42.90 inclusive.

F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 12, 2024 Filed Mar 13, 2024 23:53 UTC Kymera Therapeutics, Inc. KYMR · Entity 3545 SaleCommon Stock 126,066 $41.94 $5,287,208.04
Disclosure

SEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 5

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,799,746

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.445 to $42.43 inclusive.

F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 11, 2024 Filed Mar 13, 2024 23:53 UTC Kymera Therapeutics, Inc. KYMR · Entity 3545 SaleCommon Stock 1,045 $43.42 $45,373.90
Disclosure

SEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 4

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 881,266

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.185 to $44.03 inclusive.

F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 11, 2024 Filed Mar 13, 2024 23:53 UTC Kymera Therapeutics, Inc. KYMR · Entity 3545 SaleCommon Stock 7,837 $42.77 $335,188.49
Disclosure

SEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 3

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 882,311

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.1826 to $43.18 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7), (8), (9) and (10).

F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 11, 2024 Filed Mar 13, 2024 23:53 UTC Kymera Therapeutics, Inc. KYMR · Entity 3545 SaleCommon Stock 5,122 $43.42 $222,397.24
Disclosure

SEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 2

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,925,812

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.185 to $44.03 inclusive.

F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 11, 2024 Filed Mar 13, 2024 23:53 UTC Kymera Therapeutics, Inc. KYMR · Entity 3545 SaleCommon Stock 37,180 $42.77 $1,590,188.60
Disclosure

SEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 1

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,930,934

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.1826 to $43.18 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7), (8), (9) and (10).

F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 01, 2024 Filed Mar 5, 2024 17:07 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 17,099 $30.05 $513,824.95
Disclosure

SEC source: 0001415889-24-006764 · form4-03052024_100352.xml · nonDerivative · entry 2

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 847,388

F4 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
March 01, 2024 Filed Mar 5, 2024 17:07 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 29,435 $30.05 $884,521.75
Disclosure

SEC source: 0001415889-24-006764 · form4-03052024_100352.xml · nonDerivative · entry 1

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,458,691

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 210 $25.25 $5,302.50
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 18

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 864,487

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 13,109 $24.83 $325,496.47
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 17

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 864,697

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 360 $25.25 $9,090.00
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 16

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,488,126

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 22,567 $24.83 $560,338.61
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 15

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,488,486

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 2,430 $25.25 $61,357.50
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 14

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,698,091

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 152,244 $24.83 $3,780,218.52
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 13

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,700,521

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 2,216 $24.68 $54,690.88
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 12

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 877,806

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 23,505 $24.38 $573,051.90
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 11

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 880,022

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 3,821 $24.68 $94,302.28
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 10

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,511,053

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 40,455 $24.38 $986,292.90
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 9

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,514,874

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 25,779 $24.68 $636,225.72
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 8

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,852,765

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 272,923 $24.38 $6,653,862.74
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 7

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,878,544

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 5,580 $23.98 $133,808.40
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 6

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 903,527

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 11,736 $23.59 $276,852.24
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 5

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 909,107

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).

F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 9,603 $23.98 $230,279.94
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 4

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,555,329

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 20,205 $23.59 $476,635.95
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 3

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,564,932

F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).

F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 64,783 $23.98 $1,553,496.34
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 2

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,151,467

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:13 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 136,312 $23.59 $3,215,600.08
Disclosure

SEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 1

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,216,250

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 23, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 13,738 $22.70 $311,852.60
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 6

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 920,843

F9 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.92 inclusive.

F10 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 23, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 23,648 $22.70 $536,809.60
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 5

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 1,585,137

F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.92 inclusive.

F8 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 23, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 159,542 $22.70 $3,621,603.40
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 4

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,352,562

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.92 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 22, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 119,360 $22.66 $2,704,697.60
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 3

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,512,104

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.17 to $23.1566 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 21, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 35,164 $23.14 $813,694.96
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 2

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,631,464

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.7625 to $23.3899 inclusive.

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 21, 2024 Filed Feb 23, 2024 18:58 UTC Dyne Therapeutics, Inc. DYN · Entity 3948 SaleCommon Stock 149,337 $22.44 $3,351,122.28
Disclosure

SEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 1

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,666,628

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.75 to $22.72 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5) and (6).

F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 21:33 UTC Xilio Therapeutics, Inc. XLO · Entity 7122 SaleCommon Stock 267 $0.64 $170.88
Disclosure

SEC source: 0001209191-24-003031 · doc4.xml · nonDerivative · entry 2

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 734,546

F2 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 21:33 UTC Xilio Therapeutics, Inc. XLO · Entity 7122 SaleCommon Stock 733 $0.64 $469.12
Disclosure

SEC source: 0001209191-24-003031 · doc4.xml · nonDerivative · entry 1

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,019,563

F1 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:31 UTC Disc Medicine, Inc. IRON · Entity 2273 SaleCommon Stock 20,000 $67.65 $1,353,000.00
Disclosure

SEC source: 0001209191-24-002231 · doc4.xml · nonDerivative · entry 3

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 198,326

F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("Atlas Opportunity II"). Atlas Venture Associates Opportunity II, L.P. ("Associates II") is the general partner of Atlas Opportunity II. Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. Each of Associates II and Associates II LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity II, except to the extent of its pecuniary interest therein, if any.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:31 UTC Disc Medicine, Inc. IRON · Entity 2273 SaleCommon Stock 82,500 $67.65 $5,581,125.00
Disclosure

SEC source: 0001209191-24-002231 · doc4.xml · nonDerivative · entry 2

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 703,660

F2 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:31 UTC Disc Medicine, Inc. IRON · Entity 2273 SaleCommon Stock 47,500 $67.65 $3,213,375.00
Disclosure

SEC source: 0001209191-24-002231 · doc4.xml · nonDerivative · entry 1

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner

Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner

Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,402,186

F1 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

Read SEC document
January 12, 2024 Filed Jan 16, 2024 23:16 UTC Xilio Therapeutics, Inc. XLO · Entity 7122 SaleCommon Stock 560 $0.83 $464.80
Disclosure

SEC source: 0001209191-24-001655 · doc4.xml · nonDerivative · entry 4

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 734,813

F3 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Read SEC document
January 12, 2024 Filed Jan 16, 2024 23:16 UTC Xilio Therapeutics, Inc. XLO · Entity 7122 SaleCommon Stock 1,540 $0.83 $1,278.20
Disclosure

SEC source: 0001209191-24-001655 · doc4.xml · nonDerivative · entry 3

Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner

Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner

Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,020,296

F2 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.